In the latest trading session, 0.62 million BioXcel Therapeutics Inc (NASDAQ:BTAI) shares changed hands as the company’s beta touched -0.01. With the company’s most recent per share price at $0.31 changed hands at -$0.02 or -4.88% at last look, the market valuation stands at $15.39M. BTAI’s current price is a discount, trading about -1245.16% off its 52-week high of $4.17. The share price had its 52-week low at $0.30, which suggests the last value was 3.23% up since then. When we look at BioXcel Therapeutics Inc’s average trading volume, we note the 10-day average is 4.53 million shares, with the 3-month average coming to 1.54 million.
Analysts gave the BioXcel Therapeutics Inc (BTAI) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.25. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended BTAI as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. BioXcel Therapeutics Inc’s EPS for the current quarter is expected to be -0.32.
BioXcel Therapeutics Inc (NASDAQ:BTAI) trade information
Instantly BTAI was in red as seen in intraday trades today. With action -15.18%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -17.06%, with the 5-day performance at -15.18% in the red. However, in the 30-day time frame, BioXcel Therapeutics Inc (NASDAQ:BTAI) is -17.06% down. Looking at the short shares, we see there were 0.35 million shares sold at short interest cover period of 0.93 days.
The consensus price target for the stock as assigned by Wall Street analysts is 1, meaning bulls need an upside of 69.0% from its recent market value. According to analyst projections, BTAI’s forecast low is 1 with 1 as the target high. To hit the forecast high, the stock’s price needs a -222.58% plunge from its current level, while the stock would need to soar -222.58% for it to hit the projected low.
BioXcel Therapeutics Inc (BTAI) estimates and forecasts
Data shows that the BioXcel Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -69.89% over the past 6 months, a 75.12% in annual growth rate that is considerably higher than the industry average of 15.90%. Year-over-year growth is forecast to reach 106.09% up from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 718.26k. 2 analysts are of the opinion that BioXcel Therapeutics Inc’s revenue for the current quarter will be 350k. The company’s revenue for the corresponding quarters a year ago was 376k and 582k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 91.03%. The estimates for the next quarter sales put growth at -39.86%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -35.97%. The 2025 estimates are for BioXcel Therapeutics Inc earnings to increase by 74.51%.
BTAI Dividends
BioXcel Therapeutics Inc is expected to release its next quarterly earnings report in March.
BioXcel Therapeutics Inc (NASDAQ:BTAI)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 20.06% of BioXcel Therapeutics Inc shares while 8.76% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 10.96%. There are 8.76% institutions holding the BioXcel Therapeutics Inc stock share, with ARMISTICE CAPITAL, LLC the top institutional holder. As of 2024-06-30, the company held 9.6767% of the shares, roughly 2.99 million BTAI shares worth $3.82 million.
FMR LLC holds the second largest percentage of outstanding shares, with 7.1439% or 2.21 million shares worth $2.82 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 886.25 shares estimated at $0.28 million under it, the former controlled 1.79% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.59% of the shares, roughly 293.32 shares worth around $93863.0.
